This company has shut down. 2seventy bio is no longer operating — its last tracked round was a Post-IPO Equity in 2023.
Explore the Startup Graveyard2seventy bio is an immuno-oncology cell therapy company that discovers and develops cancer therapies.
2seventy bio has raised $125.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2023.
2seventy bio's investors include Janus Henderson Investors, RTW Investments, Bain Capital Life Sciences, Regeneron, EcoR1 Capital.
2seventy bio is headquartered in Cambridge, United States.
2seventy bio is an immuno-oncology cell therapy company that discovers and develops cancer therapies.
2seventy bio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"2seventy bio — Funding & Investors." VCBacked, February 28, 2023, https://www.vcbacked.co/company/2seventy-bio. Accessed August 13, 2026.
VCBacked. (2023). 2seventy bio — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/2seventy-bio
{{cite web |title=2seventy bio — Funding & Investors |url=https://www.vcbacked.co/company/2seventy-bio |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated